Cannara Biotech Inc. LOVFF
OTC PK
| 05/31/2026 | 02/28/2026 | 11/30/2025 | 08/31/2025 | 05/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 17.45% | 6.85% | 18.78% | 21.83% | 35.70% |
| Total Other Revenue | 745.77% | -72.97% | -71.55% | 265.93% | -9.96% |
| Total Revenue | 19.18% | 6.46% | 18.36% | 22.81% | 36.02% |
| Cost of Revenue | 18.96% | 10.55% | 25.09% | 27.95% | 11.27% |
| Gross Profit | 19.42% | 1.46% | 8.52% | 16.71% | 81.26% |
| SG&A Expenses | 26.88% | 40.56% | 42.67% | 24.72% | 14.19% |
| Depreciation & Amortization | 9.33% | -6.45% | -6.37% | 55.09% | -9.57% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.75% | 19.57% | 29.63% | 27.16% | 10.57% |
| Operating Income | 11.35% | -39.73% | -37.10% | 6.13% | 353.54% |
| Income Before Tax | 21.44% | -37.91% | -33.71% | 19.31% | 177.46% |
| Income Tax Expenses | 25.91% | -14.82% | 35.54% | 162.70% | -- |
| Earnings from Continuing Operations | 19.65% | -47.76% | -55.58% | -42.51% | 98.41% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 19.65% | -47.76% | -55.58% | -42.51% | 98.41% |
| EBIT | 11.35% | -39.73% | -37.10% | 6.13% | 353.54% |
| EBITDA | 14.81% | -35.01% | -27.34% | 11.58% | 166.96% |
| EPS Basic | 10.87% | -50.78% | -57.53% | -43.47% | 95.15% |
| Normalized Basic EPS | 12.41% | -39.30% | -35.95% | 16.28% | 28,300.00% |
| EPS Diluted | 25.70% | -50.78% | -61.29% | -50.00% | 93.20% |
| Normalized Diluted EPS | 11.87% | -39.56% | -37.09% | 15.38% | 27,900.00% |
| Average Basic Shares Outstanding | 8.04% | 6.40% | 4.11% | 1.58% | 1.57% |
| Average Diluted Shares Outstanding | 8.55% | 6.69% | 5.02% | 2.03% | 1.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |